[1] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629−640. doi: 10.1056/NEJMoa1612674 [2] Kunimasa K, Kamada R, Oka T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC Cardio Oncol 2020; 2: 1−10. doi: 10.1016/j.jaccao.2020.02.003 [3] Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol 2019; 1: 172−178. doi: 10.1016/j.jaccao.2019.10.006 [4] Watanabe H, Ichihara E, Kano H, et al. Congestive heart failure during osimertinib treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). Intern Med 2017; 56: 2195−2197. doi: 10.2169/internalmedicine.8344-16 [5] Oyakawa T, Nakashima K, Naito T. Cardiac dysfunction caused by osimertinib. J Thorac Oncol 2017; 12: e159−e160. doi: 10.1016/j.jtho.2017.05.016 [6]

Okutucu S, Sayin BY, Aksoy H, Oto A. Development of heart failure after initiation of osimertinib treatment for Epidermal Growth Factor Receptor (EGFR)-mutant adenocarcinoma of the lung. Am J Cardiol 2018; 121: e160−e161.

[7]

Reale ML, Bianco M, Tabbò F, et al. Osimertinib-induced cardiac dysfunction in EGFR-mutated lung cancer: a case series of five patients. Am J Cancer Case Rep 2018; 6: 52−60.

[8] Bian S, Tang X, Lei W. A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. BMC Pulm Med 2020; 20: 181. doi: 10.1186/s12890-020-01217-4 [9] Patel SR, Brown SN, Kubusek JE, et al. Osimertinib-induced cardiomyopathy. JACC Case Rep 2020; 2: 641−645. doi: 10.1016/j.jaccas.2019.12.038 [10] Piper-Vallillo AJ, Costa DB, Sabe MA, Asnani A. Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib. JACC Cardio Oncol 2020; 2: 119−122. doi: 10.1016/j.jaccao.2020.01.003 [11] Shinomiya S, Kaira K, Yamaguchi O, et al. Osimertinib induced cardiomyopathy: A case report. Medicine (Baltimore) 2020; 99: e22301. doi: 10.1097/MD.0000000000022301 [12] Ikebe S, Amiya R, Minami S, et al. Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma. Int Cancer Conf J 2021; 10: 68−71. doi: 10.1007/s13691-020-00450-2 [13] Kondo M, Kisanuki M, Kokawa Y, et al. Case report: QT prolongation and abortive sudden death observed in an 85-year-old female patient with advanced lung cancer treated with tyrosine kinase inhibitor osimertinib. Front Cardiovasc Med 2021; 8: 655808. doi: 10.3389/fcvm.2021.655808 [14] Zhang XY, Wu CB, Wu CX, et al. Case report: torsade de pointes induced by the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib combined with litsea cubeba. Front Cardiovasc Med 2022; 9: 903354. doi: 10.3389/fcvm.2022.903354 [15] Chen J, Zeng F, Forrester SJ, et al. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev 2016; 96: 1025−1069. doi: 10.1152/physrev.00030.2015 [16] Brown SA, Sandhu N, Herrmann J. Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol 2015; 12: 718−731. doi: 10.1038/nrclinonc.2015.168 [17] Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res 2018; 24: 2594−604. doi: 10.1158/1078-0432.CCR-17-1875 [18] [19] Guo GG, Luo X, Zhu K, et al. Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report. J Geriatr Cardiol 2023; 20: 242−246. doi: 10.26599/1671-5411.2023.03.009